Devices and Methods for Umbilical Cord Processing

Description:

Background

Cleft lip and cleft palate (CLP) is the most common birth defect in the United States, affecting more than 2,650 children born each year according to the Centers for Disease Control and Prevention. The accepted standard treatment for cleft palate is autologous bone grafting, which provides a stable repair but is invasive and can be followed by potential complications of graft exposure and loss. In addition, autologous bone grafting is subject to donor site morbidity including infection, long-term pain and/or nerve damage that lead to the need of additional surgeries. Another strategy based on using biomaterials seeded with bone marrow (BM) stem cells has proven promising, but BM harvest is too invasive to use in CLP repair in newborns. 

 

Components

Native Wharton's Jelly (nWJ) is the connective tissue of the umbilical cord, and it is composed of a network of proteoglycans and collagen embedded with perinatal stem cells, a bridge between embryonic and adult stem cells without the limitations of either. It is a natural “tissue engineering” construct that provides a scaffold derived from the recipient's own molecules, naturally seeded with the recipient's own stem cells, and is thus immunologically inert. Since nWJ is typically discarded as post-delivery medical waste, its use does not pose ethical concerns and its harvest is completely non-invasive. Researchers at UTHealth have developed a device to extract the nWJ, developed methods to process the nWJ, and have shown in an alveolar defect model representative of cleft palate surgery in the rat, that inclusion of nWJ in the alveolar pocket at the time of palate repair enhances bone growth and accelerates healing, proving to be an adjunct of great potential to orofacial cleft repair.

 

Potential Benefits/Technology Advantages

•       Enhanced bone growth and accelerated healing in cleft lip/cleft palate repair

•       Better anticipation of the timing of surgical correction

•       Reduction or elimination of the need for subsequent bone grafting.

 

Intellectual Property Status

Patent pending: PCT/US2018/049453 filed 9/5/2018 & US 15/449,085

 

About the Inventors

Charles S. Cox, Jr., M.D. is Professor of Pediatric Surgery in the McGovern Medical School.

Brijesh “Billy” Gill, M.D. is an Associate Professor of Surgery in the McGovern Medical School.

 

Download a full summary here

 

Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
Category(s):
Medical Devices
For Information, Contact:
Christine Flynn
Associate Director, Licensing and New Venture Development
University of Texas Health Science Center At Houston
Christine.Flynn@uth.tmc.edu
Inventors:
Charles Cox, Jr.
Brijesh Gill
Keywords:
© 2021. All Rights Reserved. Powered by Inteum